BRNS

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Barinthus Biotherapeutics PLC revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Barinthus Biotherapeutics PLC. EPS for the last quarter amounts to -0.36 USD, increased 71.43 % YoY.

Barinthus Biotherapeutics PLC (BRNS) has 105 emplpoyees as of December 17 2025.

Today BRNS has the market capitalization of 30.15M USD.